Total: $244.9M |
||||
Company (Symbol)# | Type Of Financing | Number Of Shares, Units Or Warrants (M) | Amount Raised (M) | Investors; Placement Agents; Details (Date)@ |
Acacia Research Corp. (ACRI) | Private placement of common shares | 1.1S | $19 | Acacia sold about 1.1M shares, raising $19M (1/23) |
Aradigm Corp. (ARDM) | Exercise of a put option | 0.34S | $5 | Aradigm raised $5M through the sale of 339,961 common shares at an average price of $14.71 to GlaxoSmithKline (1/16) |
Aviron Inc. (AVIR) | Private placement of common stock | 0.161S | $8 | Aviron sold 161,060 shares to Acqua Wellington North American Equities Fund Ltd. for an aggregate price of $8M (1/29) |
Corixa Corp. (CRXA) | Drawdown of credit line | 37.5S | $37.5 | Corixa took down the remaining $37.5M of its credit line with Castle Gate LLC; the tranche included a 37.5M Series B issuance to Castle Gate and a 10-year warrant to purchase an additional 50,000 shares of Corixa (1/2) |
Gene-Cell Inc. (OTC BB:GCLL) | Private placement of common shares | 1.875S | $1.5 | Gene-Cell raised $1.5M through the private placement of 1.875M shares (1/12) |
ImClone Systems Inc. (IMCL) | Redemption of Series A preferred stock | ND | $24 | ImClone redeemed the stock held by Merck KGaA, of Germany (1/10) |
Interleukin Genetics Inc. (ILGN) | Private placement of common shares and warrants | 1.2S 0.6W | $3 | Interleukin Genetics raised $3M in a private placement of 1.2M shares at $2.50 each and 600,000 warrants at $3 each with Special Situations Funds (1/30) |
Ligand Pharmaceuticals Inc. (LGND) | Draw down of zero-convertible notes | | $10 | Ligand drew down $10M of the notes from Elan Corp. plc under terms of a September 1998 agreement (1/4) |
Ligand Pharmaceuticals Inc. (LGND) | Private placement of common shares | 2S | $24 | Ligand completed a $24M private placement with Elan Corp. plc and other investors (1/8) |
Nexell Therapeutics Inc. (NEXL) | Private placement of common shares | ND | $25 | Nexell agreed to sell up to $25M worth of stock to Acqua Wellington North American Equities Fund Ltd. (1/10) |
Prana Biotechnology Ltd. (Australia; ASX:PBT) | Private placement of common shares | 6.66S | A$5 (US$2.8) | Prana raised US$2.8M by issuing 6.66M shares distributed by CIBC World Markets and Intersuisse Corp. Pty. Ltd. and placed with Australian and U.S. institutions (1/18) |
SafeScience Inc. (SAFS) | Private placement of common stock and warrants | 3.96S (plus warrants to purchase 1.964S) | $4.7 | SafeScience raised $4.7M in net proceeds from an institution and accredited investors; the company issued about 3.96M shares at $1.19 per share and fixed-price-cash warrants to purchase about 1.964M shares at $2.56 per share, exercisable for five years (1/16) |
SangStat Medical Corp. (SANG) | Private placement of common shares | 1.3S | $12.5 | Participants included Narragansett ILP, Narragansett Offshore Ltd., Royal Bank of Canada and SDS Capital Partners (1/9) |
Texas Biotechnology Corp. (AMEX:TXB) | Exercise of warrants | 2.57W | $21.7 | The company raised $21.7M through the exercise of about 2.57M warrants at a price of $8.44 each (1/5) |
Triangle Pharmaceuticals Inc. (VIRS) | Private placement of common stock | 7.7S | $46.2 | Triangle raised $46.2M with the private placement of 7.7M shares at $6 per share; Abbott Laboratories agreed to purchase 1.3M shares of the common stock; Bank of America Securities LLC served as placement agent (1/31) |
Notes: |
||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. |
||||
* Non-U.S. currencies converted at the exchange rate on the date of the announcement. |
||||
@ Dates refer to the date of the press release. |
||||
ASX = Australian Stock Exchange |
||||
OTC BB = Over The Counter Bulletin Board |
||||
